Health and economic impacts of Vaccae vaccination incorporating active case finding in India and South Africa: a modelling study
Open Access
- 20 September 2024
- journal article
- Published by BMJ in BMJ Public Health
- Vol. 2 (2) , e001042
Abstract
Introduction: Tuberculosis (TB) is a major global health issue, particularly, in India and South Africa. We aim to evaluate the potential of the new TB vaccine, Vaccae, to enhance TB control by integrating with active case finding (ACF) strategies in these regions. Methods: Using age-structured dynamic models, we projected the epidemiological and economic outcomes of combining Vaccae vaccination with ACF over 27 years. In India, four age-targeted strategies were analysed: (1) adolescent (15 years), (2) adolescent and young adult (AYA, 15–34 years), (3) adult (18–55 years) and (4) elderly (60+ years). In South Africa, strategies were based on HIV status: (1) HIV-targeted, (2) non-HIV and (3) general population. The vaccine efficacy of Vaccae was set at 54.7%, priced at US$120 per course. Outcomes measured included reductions in TB incidence and mortality, prioritised based on budget, incremental cost-effectiveness ratios (ICER) and benefit-cost ratios (BCR). Results: In India, the adult strategy could prevent 8.70 (95% UI: 6.86–11.13) million TB cases and 0.61 (0.39–0.91) million deaths, reducing incidence and mortality by 20.1% (18.7%–23.5%) and 19.0% (17.5%–22.5%), respectively. In South Africa, the general population strategy could avert 0.67 (0.45–0.99) million TB cases and 0.21 (0.15–0.28) million deaths, reducing incidence by 28.1% (26.1%–30.3%) and mortality by 27.0% (23.5%–30.0%). The vaccination budgets for the AYA strategy in India and the HIV-targeted strategy in South Africa were US$14.0 (10.14–23.29) billion and US$0.09 (0.06–0.15) billion, respectively. The ICERs were US$1082 (927–1426) and US$70 (53–123) per disability-adjusted life year averted, and the BCRs were 2.0 (1.6–2.4) and 176 (83.4–255.3), respectively. Thus, the AYA strategy in India and the HIV-targeted strategy in South Africa were the most favourable. Conclusion: Integrating Vaccae vaccination with ACF could significantly enhance TB control in high-burden countries. Policymakers should consider these strategies, with further research needed to confirm the findings.Keywords
Funding Information
- National Science and Technology Major Project (2022YFC2304901)
- Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX23_3434)
- Jiangsu Provincial Research Hospital (YJXYY202204-XKA02, YJXYY202204-YSA03)
This publication has 39 references indexed in Scilit:
- Modelling the health and economic impacts of M72/AS01E vaccination and BCG-revaccination: Estimates for South AfricaVaccine, 2024
- A systematic review and meta-analysis of active case finding for tuberculosis in IndiaThe Lancet Regional Health - Southeast Asia, 2022
- Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017–19: a multistage, cluster-based, cross-sectional surveyThe Lancet Infectious Diseases, 2022
- The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2022
- Latent TB (LTBI) treatment: Challenges in India with an eye on 2025Indian Journal of Tuberculosis, 2020
- Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis CApplied Health Economics and Health Policy, 2020
- Impact and cost effectiveness of pneumococcal conjugate vaccine in IndiaVaccine, 2019
- Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South AfricaVaccine, 2018
- The economic burden of TB diagnosis and treatment in South AfricaSocial Science & Medicine, 2015
- Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trialThe Lancet, 2013